Stewardship

BIO President and CEO Jim Greenwood talks with Arnold Thackray, President and CEO of the Life Sciences Foundation, about how the life sciences will shape the course of the 21st century.

Bob Coughlin discusses the elements of supportive bioscience industry climates and looks ahead to the 2012 BIO International Convention.

BIO President & CEO Jim Greenwood and Tom Watkins, President & CEO of Human Genome Sciences and Chair of BIO’s Board of Directors, recently hosted a media briefing to recap our advocacy accomplishments in 2011 and lay out BIO’s policy priorities for 2012.

Congress has the opportunity to help speed lifesaving cures and treatments to patients by removing burdens to innovation in our industry.

There are many reasons to be excited about financing early stage biotech companies. The BIO Investor Forum will assemble the most promising among promising discovery stage companies. 

In this global economy, nearly every competitor has access to big breakthroughs in technology and to the equipment and capital to produce standardized products, but those regions that possess the human capital, with its insights, competencies, and experience will have the competitive advantage.

Society has tapped just a small fraction of the many potential uses and benefits of biotechnology.